- Population
- Healthy adults aged 21–61
- Route
- Subcutaneous
- Dose as published
- Subcutaneous ascending single doses (first trial) and two or three weekly or biweekly doses (second trial); the paper reports the well-tolerated doses as 30 or 60 µg/kg
- Frequency
- Single ascending doses; weekly or biweekly in the repeat-dose trial
- Duration
- Trials lasting 28 and 49 days
- Endpoint
- Peak and AUC of GH and IGF-I
CJC-1295 · dosing reference
What dose information exists for CJC-1295?
Two distinct molecules share this name. The published human trials used the DAC (albumin-binding) form; the non-DAC fragment sold as “Mod GRF 1-29” has no comparable published human dose data in this file.
Published human study doses
Human studyIntervention parameters reported in individual published human studies. Each study stays separate; parameters are never aggregated across studies.
Clinical / professional references
Clinical ref.Protocols published by identifiable professional, clinic or pharmacy sources, recorded with author/clinic, date accessed and context.
Emphasizes distinguishing short-acting Mod GRF 1-29 (100 mcg per injection paired with a GHRP) to preserve natural physiological GH pulsatility, contrasting with continuous GHRH exposure from DAC formulations which risks pituitary receptor desensitization.
William A. Seeds, M.D. (Seeds Scientific Research & Performance Institute) — Professional medical handbook on cellular medicine and growth hormone secretagogue signaling.
Community-reported ranges
CommunityWhat people report discussing or doing in forums, on Reddit and in videos. Included only to show demand and reported practice — never as clinical evidence.
CJC-1295 DAC: typically discussed as roughly 1,000–2,000 mcg (1–2 mg) total per week (not per kg, and not daily), often split into one or two weekly administrations.
- CJC-1295 DAC incorporates an albumin-binding Drug Affinity Complex extending its elimination half-life to roughly 6–8 days. Prior internet tables that cited '100–300 mcg/kg/day' made a catastrophic unit error that conflated fixed micrograms with per-kilogram daily dosing.
- Therapept documents this distinction strictly for harm reduction and error correction; this is community reporting, not a clinical protocol.
Community reports describe what people say they are doing. They are not equivalent to clinical evidence, and discussion volume says nothing about whether a practice is safe, effective or even real.
CJC-1295 without DAC (Mod GRF 1-29): typically discussed as 100 mcg fixed amount per injection (not per kg), 1 to 3 times daily, almost always co-administered with ipamorelin.
- Mod GRF 1-29 is a 29-amino acid fragment with a half-life of ~30 minutes designed to elicit acute pulsatile GH release rather than constant elevation.
Community reports describe what people say they are doing. They are not equivalent to clinical evidence, and discussion volume says nothing about whether a practice is safe, effective or even real.
Why community reports are shown at all
People search for dose information before they search for anything else in this sector. Where discussion is widespread, pretending it does not exist helps nobody. Therapept reports the discussion — its rough shape, how common it is, and where it happens — while keeping it visibly separate from every other kind of source. Community reports describe what people say they are doing. They are not equivalent to clinical evidence.
Last reviewed 22 September 2026 · Compiled by Therapept Editorial · How these records are built
